← All trials
NCT04526132
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 14, 2020
- Primary completion
- May 30, 2021
- Completion date
- Jun 30, 2021
- First posted
- Aug 25, 2020
- Last posted
- Aug 25, 2020
- Enrollment
- 336
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yiling Pharmaceutical Inc.Lead sponsor
- Central South UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.